Experts from the John Theurer Cancer Center reflect on the real-world management of patients with myelofibrosis at their institution.
EP. 1: Patient Scenario 1: Diagnosis and Risk Stratification of MF
After reviewing the first patient scenario of myelofibrosis, experts from the John Theurer Cancer Center reflect on best practices in diagnosing and risk stratifying patients.
EP. 2: Molecular Markers and Subsets of Myelofibrosis
Expert panelists consider key molecular markers that guide the classification and management of myelofibrosis, along with other important subsets of disease.
EP. 3: Optimizing MF Management With Multidisciplinary Care
A comprehensive discussion on the members of a healthcare team who might help to diagnose and manage a patient with myelofibrosis.
EP. 4: Evolving Treatment Armamentarium for Myelofibrosis
Key opinion leaders provide a broad perspective on the current treatment armamentarium available to patients diagnosed with myelofibrosis.
EP. 5: Clinical Data With Pacritinib in Patients With Myelofibrosis
Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.
EP. 6: Myelofibrosis: Potential Impact of Pacritinib on Anemia
Experts continue their conversation on pacritinib in myelofibrosis by reviewing its potential impact on anemia and ACVR1.
EP. 7: Pacritinib in Myelofibrosis: Adverse Event Management and Dosing
Shared insight on the safety profile of pacritinib and how best to mitigate or manage adverse events when they occur in patients with myelofibrosis.
EP. 8: Momelotinib’s Role in the Myelofibrosis Treatment Paradigm
Key opinion leaders on myelofibrosis management consider the potential role of momelotinib within the current treatment paradigm.
EP. 9: Patient Scenario 2: JAK2 Inhibitors in Myelofibrosis
After reviewing the second patient scenario of myelofibrosis, experts from the John Theurer Cancer Center discuss the use of JAK inhibitors, specifically ruxolitinib, to manage patients in the frontline setting.
EP. 10: Optimal Selection and Sequencing of Therapy in Patients With Myelofibrosis
Broader perspectives on the optimal selection and sequencing of systemic therapy in patients diagnosed with myelofibrosis.
EP. 11: Factors Informing Selection and Use of JAK Inhibitors in Myelofibrosis
Panelists consider the patient and disease factors that might indicate use of a specific JAK inhibitor when managing patients with myelofibrosis.
EP. 12: Evolving Treatment Landscape of Myelofibrosis
Closing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.